Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab5475)

Submit a review Q&A (1)References (9)

Overview

  • Product name

    Anti-VEGF Receptor 2 (phospho Y1214) antibody
    See all VEGF Receptor 2 primary antibodies

  • Description

    Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214)

  • Host species

    Rabbit

  • Specificity

    VEGFR3 has not been tested, but is expected to react.

  • Tested applications

    Suitable for: WBmore details

  • Species reactivity

    Reacts with: Mouse, Human
    Predicted to work with: Rat

  • Immunogen

    Synthetic peptide (Human). The sequence is conserved in mouse and rat.

  • Positive control

    • NIH 3T3 cells transfected with full length, wild-type human VEGFR 2 and Porcine Aortic Endothelial cells transfected with a chimeric receptor consisting of the extracellular domain of the CSF 1 receptor coupled to the transmembrane and cytoplasmic domains of the mouse VEGFR 2.

Properties

Applications

Our Abpromise guarantee covers the use of ab5475 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 0.35 - 1 µg/ml. Detects a band of approximately 200 kDa.

Target

  • Function

    Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

  • Involvement in disease

    Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.

  • Sequence similarities

    Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.

  • Post-translational
    modifications

    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.

  • Cellular localization

    Membrane.
  • Information by UniProt

  • Database links

    see all

  • Alternative names

    • CD309 antibody
    • CD309 antigen antibody
    • EC 2.7.10.1 antibody
    • Fetal liver kinase 1 antibody
    • FLK-1 antibody
    • FLK1 antibody
    • FLK1, mouse, homolog of antibody
    • Kdr antibody
    • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
    • Kinase insert domain receptor antibody
    • KRD1 antibody
    • Ly73 antibody
    • Protein tyrosine kinase receptor FLK1 antibody
    • Protein-tyrosine kinase receptor flk-1 antibody
    • soluble VEGFR2 antibody
    • Tyrosine kinase growth factor receptor antibody
    • Vascular endothelial growth factor receptor 2 antibody
    • VEGFR 2 antibody
    • VEGFR antibody
    • VEGFR-2 antibody
    • VEGFR2 antibody
    • VGFR2_HUMAN antibody
    see all

Images

  • Western blot - Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab5475)
    Western blot - Anti-VEGF Receptor 2 (phospho Y1214) antibody (ab5475)
    Peptide Competition and Stimulation: Extracts prepared from CSF-1 stimulated (1-4, 6) or unstimulated (5) PAE cells transfected with a chimeric CSF-1/VEGFR2 receptor were resolved by SDS-PAGE on a 10% polyacrylamide gel and transferred to PVDF. Membranes were blocked with a 5% BSA-TBST buffer overnight at 4°C, then were incubated with 0.50 µg/mL ab5475 antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1, 5, 6), the nonphosphopeptide corresponding to the immunogen (2), a generic phosphotyrosine containing peptide (3), or, the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and bands were detected using the Tropix WesternStar method. The data show that only the peptide corresponding to ab5475 blocks the antibody signal, and the stimulation of the phospho signal after stimulating ligand is added (CSF-1 for the chimeric r

References

This product has been referenced in:

  • Chen X  et al. P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2. Cell Death Dis 10:131 (2019). Read more (PubMed: 30755600) »
  • Yang GL  et al. TNFSF15 inhibits VEGF-stimulated vascular hyperpermeability by inducing VEGFR2 dephosphorylation. FASEB J 31:2001-2012 (2017). Read more (PubMed: 28183800) »
See all 9 Publications for this product

Publishing research using ab5475? Please let us know so that we can cite the reference in this datasheet.

Customer reviews and Q&As

Show All Reviews Q&A
Submit a review Submit a question

Question

I have a question about Flk-1 antibody. Does Flk-1 expressed in all endothelial cells or just active endothelial cells, like with agiogenesis. I did a stain for mouse heart by use, CD31 ( pharmingen), Von factor VIII( abcam), and Flk-1, Both CD31 and VIII are positive in heart vessels, but Flk-1 is negative, I don't know if it is because of antibody problem, what if I use ab5475? Thanks, Sincerely,

Read More
Answer

Thank you for your enquiry. This antibody will recognize VEGFR-2 only if it is phosphorylated on Y1214.We would like to emphasize the fact that this antibody has only been tested for Western blot application.

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com